Latest Myelofibrosis News

Page 2 of 2

Syntara’s SNT-5505 Shows Promising Phase 2 Results, Secures A$15M Funding Boost

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

Victor Sage

29 Jan 2025

Top